Deferasirox Teva: Uses, Dosage & Side Effects
An oral iron chelator for the treatment of chronic iron overload caused by frequent blood transfusions in patients with thalassemia, myelodysplastic syndromes, and other anemias
Deferasirox Teva is an oral iron chelation medication containing the active substance deferasirox. It is prescribed to patients who develop chronic iron overload as a result of receiving frequent blood transfusions for conditions such as beta-thalassemia major, myelodysplastic syndromes (MDS), sickle cell disease, and other rare anemias. Blood transfusions deliver red blood cells that contain iron, and because the human body has no efficient mechanism for excreting excess iron, repeated transfusions lead to toxic iron accumulation in vital organs. Deferasirox Teva binds to this excess iron and promotes its elimination from the body, helping to prevent serious damage to the heart, liver, and endocrine glands.
Quick Facts: Deferasirox Teva
Key Takeaways
- Deferasirox Teva is an oral iron chelator that removes excess iron from the body by binding to it and promoting excretion through the feces, preventing iron-mediated organ damage in transfusion-dependent patients.
- It is approved for chronic transfusional iron overload in patients aged 6 years and older with conditions such as beta-thalassemia, myelodysplastic syndromes, and sickle cell disease, and in children aged 2–5 with beta-thalassemia when deferoxamine is inadequate.
- Regular monitoring of kidney function (serum creatinine), liver function (transaminases, bilirubin), and serum ferritin levels is mandatory throughout treatment to ensure safety and guide dose adjustments.
- The most common side effects are gastrointestinal disturbances (nausea, diarrhea, abdominal pain), skin rash, and increases in serum creatinine; taking the tablet with a light meal may improve tolerability.
- Deferasirox Teva film-coated tablets should be taken once daily, swallowed whole with water; they must not be chewed or crushed, and dosing is based on body weight and serum ferritin levels.
What Is Deferasirox Teva and What Is It Used For?
Deferasirox Teva contains the active substance deferasirox, a synthetic tridentate iron chelator that belongs to the pharmacological class of iron chelating agents. Iron is an essential trace element required for oxygen transport, energy metabolism, and numerous enzymatic processes. However, the human body lacks an efficient physiological mechanism for excreting excess iron. In healthy individuals, iron homeostasis is maintained by tightly regulated intestinal absorption. When patients require chronic blood transfusion therapy, each unit of transfused red blood cells introduces approximately 200–250 mg of iron, quickly overwhelming the body’s limited storage capacity.
Without treatment, this transfusional iron overload—also known as transfusional hemosiderosis—results in iron deposition in parenchymal tissues, particularly the liver, heart, and endocrine glands. Excess free iron catalyzes the formation of reactive oxygen species (ROS) through Fenton and Haber-Weiss reactions, causing oxidative damage to cell membranes, proteins, and DNA. Progressive organ damage manifests as liver fibrosis and cirrhosis, cardiac dysfunction (including heart failure and arrhythmias), diabetes mellitus, hypogonadism, hypothyroidism, and growth retardation in children. Cardiac complications remain the leading cause of death in transfusion-dependent thalassemia patients who do not receive adequate iron chelation therapy.
Deferasirox binds to trivalent iron (Fe3+) with high selectivity and affinity in a 2:1 stoichiometric ratio, meaning two molecules of deferasirox are required to chelate one atom of iron. This selective iron binding distinguishes deferasirox from other chelators: it has minimal affinity for zinc, copper, or other essential divalent metal ions at therapeutic doses, reducing the risk of trace element depletion. Once the iron-deferasirox complex is formed, it is excreted primarily via the feces (approximately 84% of the iron eliminated), with a small fraction excreted in the urine (approximately 8%).
Deferasirox Teva is indicated for the following clinical situations:
- Chronic transfusional iron overload in patients aged 6 years and older: This includes patients receiving regular blood transfusions for conditions such as beta-thalassemia major, myelodysplastic syndromes (MDS), sickle cell disease, Diamond-Blackfan anemia, and other rare transfusion-dependent anemias. Treatment is typically initiated after the patient has received approximately 20 units (approximately 100 mL/kg) of packed red blood cells, or when serum ferritin consistently exceeds 1,000 µg/L.
- Chronic transfusional iron overload in children aged 2 to 5 years with beta-thalassemia major: Deferasirox is used in this younger age group when deferoxamine therapy is contraindicated or inadequate. This ensures that young children who cannot tolerate subcutaneous deferoxamine infusions still receive effective iron chelation.
- Non-transfusion-dependent thalassemia (NTDT) syndromes: In patients aged 10 years and older with thalassemia syndromes who do not require regular transfusions but have developed iron overload (liver iron concentration ≥ 5 mg Fe/g dry weight and serum ferritin > 800 µg/L), deferasirox may be used to reduce iron burden.
The development of oral iron chelation therapy represented a transformative advance in the management of transfusion-dependent patients. Before deferasirox, the standard iron chelator was deferoxamine (Desferal), which requires prolonged subcutaneous or intravenous infusion over 8–12 hours, typically 5–7 nights per week. This demanding regimen leads to significant adherence challenges, particularly in children and adolescents. Deferasirox, as a once-daily oral medication, dramatically simplified iron chelation therapy and has been shown to improve patient adherence and quality of life in numerous clinical studies.
Without adequate iron chelation, patients receiving regular blood transfusions accumulate approximately 0.3–0.5 mg/kg/day of iron. Over time, this leads to progressive organ damage. Studies have demonstrated that consistent iron chelation therapy significantly reduces cardiac mortality, delays liver fibrosis, and preserves endocrine function. The goal of chelation is to maintain body iron at safe levels, typically targeting serum ferritin below 1,000 µg/L and liver iron concentration below 7 mg Fe/g dry weight.
What Should You Know Before Taking Deferasirox Teva?
Deferasirox Teva is a potent medication that requires careful patient selection and ongoing monitoring. Before initiating treatment, your healthcare provider will conduct a thorough evaluation of your overall health, organ function, and current medications to determine whether deferasirox is appropriate and safe for you. Understanding the contraindications, warnings, and precautions is essential for safe and effective therapy.
Contraindications
Deferasirox Teva must not be used in the following situations:
- Hypersensitivity to deferasirox or any excipient: Patients with a known allergy to deferasirox or any component of the tablet formulation must not take this medication. Allergic reactions have included severe skin reactions and anaphylaxis.
- Estimated creatinine clearance below 40 mL/min: Deferasirox is cleared through the kidneys and can cause renal toxicity. Patients with severely impaired kidney function are at unacceptable risk of further deterioration.
- Advanced liver disease (Child-Pugh C): Patients with severe hepatic cirrhosis should not receive deferasirox due to the risk of hepatic failure. The drug undergoes hepatic metabolism and may worsen existing liver damage.
Additionally, the combination of deferasirox with other iron chelating agents (such as deferoxamine or deferiprone) is generally not recommended outside of specialist-supervised protocols, as the combined chelation may increase the risk of excessive metal depletion and other adverse effects.
Warnings and Precautions
Several important warnings apply to the use of deferasirox. Your physician should discuss these with you before treatment begins:
- Renal toxicity: Deferasirox can cause acute kidney injury, renal tubular damage (including Fanconi syndrome), and increases in serum creatinine. Cases of renal failure requiring dialysis and fatal outcomes have been reported, predominantly in patients with multiple comorbidities and advanced disease states. Serum creatinine must be measured before initiating treatment, weekly during the first month, and at least monthly thereafter. If creatinine rises by more than 33% above the average pre-treatment value on two consecutive measurements, the dose should be reduced by 10 mg/kg/day (for the film-coated tablet formulation).
- Hepatotoxicity: Hepatic failure, sometimes fatal, has been reported in patients treated with deferasirox. Most cases occurred in patients over 55 years with significant comorbidities including liver cirrhosis and multi-organ failure. Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) should be checked before treatment, every two weeks during the first month, and at least monthly thereafter. Treatment should be interrupted if persistent and progressive elevations in liver transaminases cannot be attributed to other causes.
- Gastrointestinal hemorrhage: Upper gastrointestinal ulceration and hemorrhage, including fatal cases, have been reported. The risk may be increased in elderly patients, in those taking concomitant medications that impair platelet function or anticoagulants (such as NSAIDs, corticosteroids, oral anticoagulants, or antiplatelet agents), and in patients with low platelet counts.
- Skin reactions: Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Treatment should be discontinued immediately if a severe skin reaction is suspected.
- Auditory and ocular disturbances: High-frequency hearing loss, decreased hearing, and lens opacities (cataracts) have been reported. Annual auditory and ophthalmologic assessments are recommended.
- Cytopenias: Agranulocytosis, neutropenia, and thrombocytopenia, sometimes with fatal infection, have been reported. Regular blood count monitoring is required, and treatment should be interrupted if unexplained cytopenias develop.
Serum creatinine, liver function tests, and complete blood counts must be monitored regularly during treatment with Deferasirox Teva. Failure to monitor may result in undetected organ damage. Always attend all scheduled blood tests and clinical appointments. Report any symptoms such as dark urine, jaundice, unusual fatigue, blood in stool, or reduced urine output to your doctor immediately.
Pregnancy and Breastfeeding
Deferasirox should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the fetus. Animal reproductive studies have shown adverse effects on embryo-fetal development, including skeletal malformations and embryotoxicity at doses equivalent to or lower than those used therapeutically in humans. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to use effective contraception during treatment and for one month after the last dose.
It is not known whether deferasirox is excreted in human breast milk. In animal studies, deferasirox and its metabolites were detected in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. Breastfeeding is not recommended during treatment with deferasirox.
There are limited data on the effect of deferasirox on fertility in humans. Animal studies have shown no direct effects on fertility, but testicular findings (tubular atrophy) have been observed at doses higher than the maximum recommended human dose. Male patients concerned about fertility should discuss this with their healthcare provider before starting treatment.
How Does Deferasirox Teva Interact with Other Drugs?
Deferasirox is metabolized primarily by UDP-glucuronosyltransferases (UGT1A1 and UGT1A3), with minor involvement of cytochrome P450 enzymes (mainly CYP1A2). Importantly, deferasirox is also an inhibitor of certain CYP enzymes and drug transporters, which means it can affect the plasma levels and efficacy of other medications. Understanding these interactions is critical for safe co-prescribing.
Major Interactions
| Drug | Mechanism | Effect | Recommendation |
|---|---|---|---|
| Theophylline | CYP1A2 inhibition by deferasirox | Increased theophylline plasma levels (up to 84% increase in AUC) | Monitor theophylline levels closely; dose reduction may be needed |
| Repaglinide | CYP2C8 inhibition by deferasirox | Increased repaglinide levels (up to 2.3-fold increase in AUC) | Combination not recommended; risk of hypoglycemia |
| Aluminum-containing antacids | Formation of chelation complexes in the GI tract | Reduced deferasirox absorption | Do not take together; separate by at least 2 hours |
| NSAIDs / Anticoagulants | Additive GI mucosal toxicity | Increased risk of GI hemorrhage and ulceration | Use with extreme caution; monitor for GI bleeding |
| Cholestyramine | Interruption of enterohepatic recycling | Reduced deferasirox exposure (45% decrease in AUC) | Avoid concomitant use |
Minor Interactions
| Drug | Mechanism | Effect | Recommendation |
|---|---|---|---|
| Midazolam | CYP3A4 induction by deferasirox | Decreased midazolam levels (up to 17% decrease) | Monitor efficacy of CYP3A4 substrates |
| Cyclosporine | Possible CYP3A4 induction | Potentially decreased cyclosporine levels | Monitor cyclosporine blood levels; adjust dose if needed |
| Paclitaxel | CYP2C8 inhibition by deferasirox | Potentially increased paclitaxel exposure | Use with caution; monitor for paclitaxel toxicity |
| Hormonal contraceptives | Potential UDP-glucuronosyltransferase induction | Theoretical risk of decreased efficacy | Additional barrier contraception may be advisable |
Patients should inform their healthcare provider about all prescription and over-the-counter medications, herbal supplements, and dietary supplements they are taking before starting Deferasirox Teva. Some food items, particularly those high in iron (such as fortified cereals and red meat) or calcium, may theoretically affect iron chelation but are unlikely to be clinically significant at normal dietary intake. Avoid taking iron supplements while on deferasirox unless specifically instructed by your doctor.
What Is the Correct Dosage of Deferasirox Teva?
Deferasirox Teva dosing is individualized based on body weight, transfusion rate, and therapeutic goals. The film-coated tablet formulation (which is the Deferasirox Teva product) has different dose levels compared to the older dispersible tablet formulation. It is critical not to interchange these formulations on a milligram-per-milligram basis, as their bioavailability differs. Your doctor will prescribe the correct dose for the specific formulation you are receiving.
Adults
Transfusion-Dependent Iron Overload (Adults)
Starting dose: 14 mg/kg/day as a single oral dose
Dose adjustments: Increase by 3.5–7 mg/kg/day every 3–6 months if serum ferritin remains above 2,500 µg/L and does not show a decreasing trend
Maximum dose: 28 mg/kg/day
Dose reduction: Consider reducing when serum ferritin falls below 1,000 µg/L; do not exceed 14 mg/kg/day when ferritin is below 1,000 µg/L
Treatment interruption: Interrupt when serum ferritin falls below 500 µg/L
Non-Transfusion-Dependent Thalassemia (Adults ≥ 10 years)
Starting dose: 7 mg/kg/day
Dose adjustment: May increase to 14 mg/kg/day after 4 weeks if LIC is ≥ 15 mg Fe/g dw or serum ferritin > 2,000 µg/L
Maximum dose: 14 mg/kg/day
Treatment interruption: Stop when LIC falls below 3 mg Fe/g dw or serum ferritin below 300 µg/L
Children
Transfusion-Dependent Children (6 years and older)
The dosing principles are the same as for adults: initial dose 14 mg/kg/day, with adjustments in increments of 3.5–7 mg/kg/day based on serum ferritin trends. The maximum dose is 28 mg/kg/day. Children tend to have higher clearance rates per kilogram and may require relatively higher doses to achieve adequate chelation.
Transfusion-Dependent Children (2 to 5 years, beta-thalassemia major)
The starting dose is 14 mg/kg/day when deferoxamine is contraindicated or inadequate. Dose adjustments follow the same principles as older children. Careful monitoring of growth, kidney, and liver function is especially important in this age group.
Elderly
Elderly patients (65 years and older) may be at increased risk of adverse reactions, particularly renal impairment, hepatotoxicity, and gastrointestinal hemorrhage. No specific dose adjustment is recommended based on age alone, but close monitoring of renal and hepatic function is especially important. Elderly patients with pre-existing renal impairment should start at the lower end of the dosing range, and dose escalation should be performed cautiously with frequent creatinine monitoring.
Missed Dose
If you miss a dose of Deferasirox Teva, take it as soon as you remember on the same day. If it is already time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Consistent daily adherence is important for maintaining effective iron chelation, so try to take Deferasirox Teva at the same time each day to establish a routine.
Overdose
Cases of overdose with deferasirox have been reported. Symptoms of overdose may include nausea, vomiting, headache, and diarrhea. More serious complications could include acute renal failure and liver injury. There is no specific antidote for deferasirox overdose. Treatment is supportive and symptomatic. In the event of an overdose, inducing vomiting or performing gastric lavage may be considered if the ingestion is recent. Immediate medical attention should be sought, and monitoring of renal function, liver function, and electrolytes should be initiated. Deferasirox is not significantly removed by hemodialysis due to its high protein binding.
The film-coated tablet formulation (Deferasirox Teva) is not interchangeable on a milligram-for-milligram basis with the older dispersible tablet formulation (e.g., Exjade dispersible tablets). The film-coated formulation has approximately 40% higher bioavailability. If switching from dispersible tablets to film-coated tablets, the dose should be reduced by approximately 30% (rounded to the nearest whole tablet). Always follow your doctor’s prescribed dose exactly.
What Are the Side Effects of Deferasirox Teva?
Like all medications, Deferasirox Teva can cause side effects, although not everyone experiences them. The frequency and severity of adverse reactions vary between patients and are influenced by factors such as dose, duration of treatment, age, underlying disease, and concomitant medications. Clinical trials involving thousands of patients have established a well-characterized safety profile for deferasirox.
Side effects are categorized below by frequency, following international conventions: very common (affects more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), and rare (fewer than 1 in 1,000).
Very Common
Affects more than 1 in 10 patients
- Increased serum creatinine
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Elevated liver transaminases (ALT/AST)
Common
Affects 1 in 10 to 1 in 100 patients
- Headache
- Skin rash (often mild, may resolve spontaneously)
- Itching (pruritus)
- Abdominal distension
- Constipation
- Dyspepsia (indigestion)
- Proteinuria (protein in urine)
- Fatigue
- Elevated blood bilirubin
- Decreased appetite
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- High-frequency hearing loss
- Lens opacities (early cataracts)
- Maculopathy (retinal changes)
- Gastrointestinal ulceration
- Gastrointestinal hemorrhage
- Duodenitis (inflammation of the duodenum)
- Gallstones (cholelithiasis)
- Pigmentation disorders
- Renal tubular disorder (including Fanconi syndrome)
- Anxiety, sleep disorders
- Dizziness
Rare
Affects fewer than 1 in 1,000 patients
- Acute renal failure
- Hepatic failure (sometimes fatal)
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Agranulocytosis
- Neutropenia / thrombocytopenia
- Optic neuritis
- Hyperammonemic encephalopathy (in MDS patients)
- Anaphylactic reactions
Gastrointestinal side effects are the most frequently reported and are often dose-related. They tend to be most pronounced during the first few weeks of treatment and may improve over time as the body adjusts to the medication. Taking Deferasirox Teva with a light meal (rather than on an empty stomach) can help reduce nausea and abdominal discomfort. If gastrointestinal symptoms are severe or persistent, your doctor may reduce the dose temporarily and then re-escalate gradually.
Increases in serum creatinine are generally mild and non-progressive in most patients. However, some patients experience progressive renal impairment requiring dose reduction or treatment discontinuation. Proteinuria, including renal tubular proteinuria, has also been observed. The mechanism of renal toxicity is not fully understood but may involve direct tubular damage by the drug or its metabolites.
Skin rash occurs in approximately 7–11% of patients and is usually mild, maculopapular in nature, and resolves spontaneously or with symptomatic treatment. However, in rare cases, severe cutaneous adverse reactions (SCARs) have been reported, requiring immediate discontinuation. Patients should be instructed to seek immediate medical attention if they develop widespread blistering, mucosal involvement, or systemic symptoms in association with a rash.
Contact your doctor or seek emergency care immediately if you experience: severe abdominal pain or black/bloody stools (possible GI hemorrhage); significantly reduced urine output, dark urine, or unusual swelling (possible kidney injury); yellowing of skin or eyes, dark urine, extreme fatigue (possible liver failure); widespread skin blistering or peeling (possible severe skin reaction); signs of infection with high fever (possible agranulocytosis).
How Should You Store Deferasirox Teva?
Proper storage of medication is essential to ensure it remains effective and safe throughout its shelf life. Deferasirox Teva film-coated tablets should be stored under the following conditions:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze the tablets.
- Packaging: Keep the tablets in the original blister packaging to protect from moisture. Do not remove tablets from the blister until you are ready to take them.
- Light: No special light protection is required, but storing in the original packaging is recommended.
- Children: Keep out of the reach and sight of children. Iron chelators can be dangerous if taken by individuals who do not have iron overload, as excessive iron removal can lead to symptomatic iron deficiency.
- Expiry date: Do not use Deferasirox Teva after the expiry date stated on the carton and blister packaging. The expiry date refers to the last day of that month.
Do not dispose of medications in household waste or via the wastewater system. Ask your pharmacist about proper disposal of medicines you no longer need. These measures help protect the environment and prevent accidental exposure.
What Does Deferasirox Teva Contain?
Understanding the composition of your medication can be important, particularly if you have known allergies or intolerances to specific excipients. Deferasirox Teva film-coated tablets contain the following:
- Active substance: Deferasirox. Each tablet contains 90 mg, 180 mg, or 360 mg of deferasirox, depending on the strength prescribed.
- Tablet core excipients: Microcrystalline cellulose (filler/binder), crospovidone (disintegrant), povidone (binder), sodium lauryl sulfate (wetting agent), magnesium stearate (lubricant), colloidal anhydrous silica (glidant).
- Film coating: Hypromellose (coating agent), titanium dioxide E171 (colorant), macrogol/polyethylene glycol (plasticizer), talc (anti-adherent). Additional colorants may vary by tablet strength (e.g., indigo carmine aluminum lake E132 for certain strengths).
Deferasirox Teva film-coated tablets are bioequivalent to the reference product (Exjade film-coated tablets/Jadenu) and have been approved through a rigorous regulatory process that demonstrates pharmaceutical equivalence and comparable clinical performance. The film-coated tablet formulation offers significant advantages over the older dispersible tablet formulation, including simpler administration (swallow whole with water rather than dispersing in liquid), improved palatability, and higher bioavailability, allowing for lower doses to achieve equivalent therapeutic effect.
The tablets do not contain lactose, gluten, or gelatin. However, patients with specific excipient sensitivities should review the full list of ingredients in the package leaflet or consult their pharmacist. Deferasirox Teva tablets contain sodium but in negligible amounts per tablet (less than 1 mmol per dose), making them essentially sodium-free.
Frequently Asked Questions About Deferasirox Teva
The film-coated tablet (FCT) formulation, used in Deferasirox Teva, has approximately 40% higher bioavailability than the older dispersible tablet (DT) formulation. This means lower doses are needed to achieve the same therapeutic effect. Film-coated tablets are swallowed whole with water, whereas dispersible tablets must be dissolved in water or juice before drinking. The FCT formulation is generally better tolerated with fewer gastrointestinal side effects and simpler administration. If switching from dispersible tablets to film-coated tablets, the dose must be reduced by approximately 30% to avoid over-chelation. These two formulations are not interchangeable on a milligram-per-milligram basis.
Iron chelation therapy with Deferasirox Teva is generally a long-term treatment that continues as long as blood transfusions are ongoing and iron overload persists. For transfusion-dependent patients, this often means treatment for many years or even for life. The goal is to maintain serum ferritin levels below 1,000 µg/L and liver iron concentration at safe levels. Treatment may be temporarily interrupted if ferritin falls below 500 µg/L, but it is usually resumed when iron accumulation begins again. For non-transfusion-dependent thalassemia, treatment may be interrupted when iron stores have been adequately reduced and resumed if they rise again. Your hematologist will guide the duration based on your individual clinical situation.
There is no specific contraindication to moderate alcohol consumption with deferasirox. However, because deferasirox can affect liver function and cause hepatotoxicity, and because alcohol also puts stress on the liver, caution is advised. Patients with pre-existing liver disease or elevated liver enzymes should avoid alcohol entirely. Even in patients with normal liver function, excessive alcohol intake could increase the risk of liver damage. Discuss your alcohol consumption honestly with your doctor, who can provide personalized advice based on your liver function test results and overall clinical status.
If your serum ferritin falls below 500 µg/L during treatment with deferasirox, your doctor should consider interrupting treatment. Over-chelation, where too much iron is removed, can lead to symptomatic iron deficiency with symptoms such as fatigue, weakness, pallor, and reduced exercise tolerance. In severe cases, excessive chelation can deplete iron stores to dangerously low levels. This is why regular monitoring of serum ferritin (at least monthly) is essential. The dose should be gradually reduced as ferritin approaches the target range, rather than waiting until it drops too low. When transfusions resume and iron levels begin to rise again, chelation therapy can be restarted.
Deferasirox Teva contains the same active substance (deferasirox) as the originator products Exjade and Jadenu, both manufactured by Novartis. Exjade was the original brand, initially available only as dispersible tablets. Jadenu was later introduced as a film-coated tablet formulation with improved bioavailability and convenience. Deferasirox Teva is a generic version of the film-coated tablet formulation, approved through regulatory pathways that require demonstration of bioequivalence to the reference product. This means it delivers the same amount of active substance to the bloodstream and is expected to have the same efficacy and safety profile. Generic medications undergo rigorous quality testing and must meet the same pharmaceutical standards as the originator product.
Several blood tests are required for safe monitoring during deferasirox therapy. Serum creatinine should be checked before starting, weekly during the first month, then monthly. Liver function tests (ALT, AST, bilirubin) should be checked before starting, every two weeks during the first month, then monthly. Serum ferritin should be monitored monthly to guide dose adjustments. Complete blood count (CBC) should be checked regularly (typically monthly) to detect cytopenias. Urinalysis for proteinuria should be performed monthly. Additionally, annual auditory assessments (hearing tests) and ophthalmologic examinations (eye checks including retinal examination) are recommended to detect early auditory or visual changes.
References
- European Medicines Agency (EMA). Deferasirox – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). JADENU (deferasirox) – Prescribing Information. Revised 2024. Available at: www.fda.gov
- Cappellini MD, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462. doi:10.1182/blood-2005-08-3430
- Cappellini MD, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566. doi:10.3324/haematol.2009.014696
- Taher AT, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977. doi:10.1182/blood-2012-02-412692
- Thalassaemia International Federation (TIF). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 4th edition, 2023.
- British Society for Haematology (BSH). Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK. 3rd edition, 2022.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd list, 2023. Deferasirox is listed as an essential medicine for iron overload.
- Pennell DJ, et al. Deferasirox for thalassemia major: effects on cardiac iron and function assessed by cardiovascular magnetic resonance. Blood. 2014;123(10):1464–1471. doi:10.1182/blood-2013-04-490738
- Goldberg SL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847–2852. doi:10.1200/JCO.2009.25.2395
Editorial Team
This article has been written and reviewed by qualified medical professionals with expertise in hematology and clinical pharmacology. All medical information is based on current international guidelines and peer-reviewed research.
Medical Content Team
Licensed physicians specializing in hematology, internal medicine, and clinical pharmacology with expertise in iron chelation therapy and transfusion medicine.
Medical Review Board
Independent panel of specialist physicians who verify all medical claims against current evidence, international guidelines (EMA, FDA, WHO, BSH, TIF), and the GRADE evidence framework.
Accessibility Team
Specialists in web accessibility ensuring WCAG 2.2 Level AAA compliance, screen reader compatibility, and inclusive design for all users.
Editorial Standards
Evidence Level 1A. No pharmaceutical sponsorship. Independent editorial content. Full conflict-of-interest disclosure. Regular content updates based on new evidence.